Related Experiment Videos
Immune responses to adeno-associated virus vectors
Anne K Zaiss1, Daniel A Muruve
1Department of Biochemistry & Molecular Biology, University of Calgary, 3330 Hospital Drive N.W., Calgary, Alberta T2N 4N1, Canada.
Current Gene Therapy
|June 25, 2005
Summary
Adeno-associated virus (AAV) vectors are promising for gene therapy due to low immunogenicity. However, immune responses against AAV can limit treatment efficacy and re-administration, necessitating strategies to overcome these challenges.
Area of Science:
- Immunology
- Gene Therapy
- Virology
Background:
- Viral vectors, particularly adeno-associated virus (AAV) vectors, are crucial for gene therapy.
- AAV vectors exhibit low immunogenicity and toxicity, promoting vector persistence and long-term transgene expression.
- However, immune responses against AAV vectors and transgene products pose significant challenges in clinical applications.
Purpose of the Study:
- To review innate and adaptive immune responses to AAV vectors.
- To discuss the mechanisms underlying these immune responses.
- To outline strategies for circumventing immune responses in AAV-mediated gene therapy.
Main Methods:
- Review of existing literature on AAV immunogenicity.
- Analysis of factors influencing immune responses to AAV vectors and transgene products.
- Summarization of strategies to mitigate immune responses.
Main Results:
- AAV vectors can elicit both humoral and cellular immune responses.
- Antibodies against AAV capsids neutralize vector efficacy and prevent re-administration.
- Immune responses to transgene products depend on various factors including transgene, promoter, administration route, dose, and host factors.
Conclusions:
- Understanding AAV immune responses is critical for successful gene therapy.
- Strategies like capsid modification, alternative serotypes, and immunosuppression can overcome immune barriers.
- Further research is needed to optimize AAV vector design and administration for enhanced safety and efficacy.